News archive
- April 2022
- March 2022
- February 2022
- January 2022
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- October 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- December 2019
- November 2019
- October 2019
- August 2019
- July 2019
- June 2019
- April 2019
- February 2019
- January 2019
- November 2018
- October 2018
- September 2018
- June 2018
- May 2018
- April 2018
- February 2018
- December 2017
- August 2017
- June 2017
- November 2016
- October 2016
- June 2016
- December 2015
- April 2015
- January 2015
Results of the most important study on effectiveness and safety of Mexidol (EPICA) have been published
23.08.2017
LLC "SPC "PHARMASOFT" informed about completion of randomized, double-blind, multicenter, placebo-controlled in parallel groups study of effectiveness and safety of Mexidol in long-term sequential therapy in patients with hemispheric ischemic stroke EPICA in acute and early rehabilitation periods. The results of the study have been published (Stakhovskaya L.V., Shamalov N.A., Khasanova D.R., Melnikova E.V., et al. Journal of Neurology & Psychiatry named after S.S. Korsakov2017; 3 (2):55-65; Supplement "Stroke").